Biogen (BIIB) Non-Current Debt (2009 - 2026)
Biogen (BIIB) posted quarterly Non-Current Debt of $7.3 billion for Q2 2026, up 16.02% year-over-year from $6.3 billion in Q2 2025, and up 15.93% quarter-over-quarter from $6.3 billion in Q1 2026.
Biogen (BIIB) Non-Current Debt (2009 - 2026) Analysis & Trends
Biogen's Non-Current Debt history runs 18 years deep, the most recent figure standing at $7.3 billion for Q2 2026.
- In Q2 2026, Non-Current Debt rose 16.02% year-over-year to $7.3 billion; the TTM figure through Jun 2026 stood at $7.3 billion (up 16.02% YoY), while the FY2025 annual figure was $6.3 billion, up 38.26% from the prior year.
- Non-Current Debt for Q2 2026 stood at $7.3 billion, up from $6.3 billion in the prior quarter.
- The five-year high for Non-Current Debt was $7.3 billion in Q2 2026, with the low at $4.5 billion in Q4 2024.
- The 5-year median for Non-Current Debt is $6.3 billion (2024), against an average of $6.4 billion.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt plunged 33.01% in 2024, then jumped 38.26% in 2025.
- Biogen's Non-Current Debt stood at $6.3 billion in 2022, then climbed by 8.08% to $6.8 billion in 2023, then slumped by 33.01% to $4.5 billion in 2024, then surged by 38.26% to $6.3 billion in 2025, then advanced by 15.96% to $7.3 billion in 2026.
- Business Quant data shows BIIB's Non-Current Debt at $7.3 billion in Q2 2026, $6.3 billion in Q1 2026, and $6.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 7.29 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.29 Bn |
| Mar 31, 2026 | 6.29 Bn |
| Dec 31, 2025 | 6.29 Bn |
| Sep 30, 2025 | 6.29 Bn |
| Jun 30, 2025 | 6.28 Bn |
| Mar 31, 2025 | 6.30 Bn |
| Dec 31, 2024 | 4.55 Bn |
| Sep 30, 2024 | 6.29 Bn |
| Jun 30, 2024 | 6.29 Bn |
| Mar 31, 2024 | 6.54 Bn |
| Dec 31, 2023 | 6.79 Bn |
| Sep 30, 2023 | 6.79 Bn |
| Jun 30, 2023 | 6.28 Bn |
| Mar 31, 2023 | 6.28 Bn |
| Dec 31, 2022 | 6.28 Bn |
| Sep 30, 2022 | 6.28 Bn |
| Jun 30, 2022 | 7.28 Bn |
| Mar 31, 2022 | 7.28 Bn |
| Dec 31, 2021 | 6.27 Bn |
| Sep 30, 2021 | 7.27 Bn |